Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal
Tweet Send to a Friend
Stifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
